Sandoz has completed acquisition of EBEWE Pharma’s specialty generic injectables business for $1.3 billion.
The transaction offers Sandoz a complementary portfolio of differentiated generics, with more than 15 marketed products and a strong pipeline with several near-term launches. The company said that Sandoz and EBEWE Pharma will focus on implementing their joint integration plans to deliver a smooth transition for all stakeholders.
A new global business unit and center of excellence is being created in Unterach, Austria, to improve customer service worldwide.
Jeff George, CEO of Sandoz, said: “We are delighted to combine EBEWE Pharma’s portfolio and pipeline of high-quality injectables with our global leadership in biopharmaceuticals, anti-infectives and other innovative technologies. This will greatly enhance the range of affordable generic anti-cancer medicines Sandoz offers to patients worldwide.”